Skip to main content
. Author manuscript; available in PMC: 2023 Apr 29.
Published in final edited form as: J Neurosurg. 2021 Oct 29;136(6):1567–1575. doi: 10.3171/2021.6.JNS21925

Figure 3:

Figure 3:

Survival of patients with moderately diffuse tumors by SMR threshold of 50% among patients with GBM with GTR of the contrast-enhancing portion. The mean survival for patients receiving < 50% SMR was 16.1 months compared with 23.4 months for those receiving > 50% SMR (p = 0.017). Figure is available in color online only.